Health Discovery Corporation Licenses New Prostate Cancer Test to Abbott

SAVANNAH, Ga.--(BUSINESS WIRE)--February 5, 2009--Health Discovery Corporation (OTCBB: HDVY) today announced that it has entered into an agreement with Abbott (NYSE: ABT) to commercialize HDC’s new molecular diagnostics gene-based tests for clinically significant prostate cancer. Abbott has acquired co-exclusive clinical laboratory rights and exclusive in vitro diagnostic rights for commercialization of HDC’s tissue-based prostate cancer test as well as HDC’s urine-based prostate cancer test.

Full article >> http://www.emailwire.com/release/19479-Health-Discovery-Corporation-Licenses-New-Prostate-Cancer-Test-to-Abbott.html